Impact Factor
3.41
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.68
238 total citations
h5-index
24
h5 depth signal
Cited share
78.3%
54 of 69
Total citations
238
Citation footprint
Metric signal
3.49
External metric anchor
Self-citation
1.3%
3 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
316
United States
59
Italy
23
South Korea
21
United Kingdom
20
Citing Fields of Research
Cardiology
445
Lipids
48
Diabetes
43
Vascular Disorders
37
Noncoding RNA
34
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,068
Articles tracked across the journal lifetime
Indexed publication set
69
54 cited publications
Last 12 months
92
92.0 publications/month
Open access share
100.0%
92 OA publications in the last year
Leading citing country
China
316 citing publications
Leading citing field
Cardiology
445 citing publications
Latest tracked publication
28 January 2026
10 recent records available
Coverage & Indexing History
v26n1, Spring 2008-
v26n1, Spring 2008-
Active Coverage
Research Focus & Classification
Indexed Subjects
Cardiology
Broad Categories
Cardiology
Therapeutics
Vascular Diseases
MeSH Descriptors
Cardiovascular Agents
Cardiovascular Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1155/cdr/9082023
Open DOI
Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR‐ α : Mechanistic Insights and Therapeutic Implications
Hyperlipidemia remains a leading modifiable risk factor for cardiovascular morbidity and mortality. Statins are considered the cornerstone of treatment; however, their adverse effects and limited efficacy in certain patient populations n...
02
DOI 10.1155/cdr/2106637
Open DOI
Elevated Resting Heart Rate in Hospitalized Patients With Atrial Fibrillation Is Associated With Increased Cardiovascular Risk
Background: Effective rate control is important in the management of atrial fibrillation (AF). However, the relationship between resting heart rate (RHR) and adverse outcomes in hospitalized patients remains uncertain. Objective: This st...
03
DOI 10.1155/cdr/6345873
Open DOI
The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta‐Analysis and Trial Sequential Analysis
Aim: This network meta‐analysis (NMA) evaluated four novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for hypercholesterolemia management, comparing their lipid‐lowering efficacy and safety. Methods: We s...
04
DOI 10.1155/cdr/6691842
Open DOI
Nonlinear and Age‐Specific Associations Between Atherogenic Index of Plasma and Differential Cardiovascular Risk Profiles in US Adults
Background: The association between the atherogenic index of plasma (AIP) and different cardiovascular disease (CVD) outcomes remains insufficiently studied. Methods: Data from 16,302 US adults in NHANES 2005–2020 were analyzed. CVD outc...
05
DOI 10.1155/cdr/8733628
Open DOI
Correlation Between ALDH2 Gene Polymorphism and Coronary Artery Disease in Patients With Atrial Fibrillation
Objectives: The objectives of this study is to investigate the correlation between genotype polymorphism of aldehyde dehydrogenase 2 (ALDH2) and coronary artery disease (CAD) in atrial fibrillation patients. Methods: From November 2020 t...
06
DOI 10.1155/cdr/3055531
Open DOI
From the Liver to Heart in Nonalcoholic Fatty Liver Disease: Single‐Cell and Serum Evidence for Cytokeratin 18 in Predicting Cardiovascular Risk
Background: This study is aimed at measuring the expression of serum cytokeratin 18 (CK18) in patients with nonalcoholic fatty liver disease (NAFLD) and at evaluating its ability to discriminate NAFLD patients with and without coronary h...
07
DOI 10.1155/cdr/9984822
Open DOI
Efficacy and Safety of Olezarsen in Patients With Hypertriglyceridemia: A Meta‐Analysis of Randomized Controlled Trials
Aims: Novel drugs that target apoC‐III in lipoprotein metabolism to reduce plasma triglycerides are currently under development. Olezarsen, a drug similar to its predecessor, volanesorsen, is in Phase 3 trials. A meta‐analysis of RCTs wa...
08
DOI 10.1155/cdr/5289405
Open DOI
Aldehyde Dehydrogenase‐2 Alleviates Septic Myocardial Injury by Inhibiting Caspase‐11‐Mediated Noncanonical Pyroptosis
Purpose: The purpose of this study is to investigate the role of aldehyde dehydrogenase‐2 (ALDH2) in septic myocardial injury, focusing on noncanonical pyroptosis. Methods: In vivo, C57BL/6J mice were divided into five groups: Sham, ceca...
09
DOI 10.1155/cdr/5690104
Open DOI
Low‐Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real‐World Study in China
Aims: To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results: This single‐center observational st...
10
DOI 10.1155/cdr/9940175
Open DOI
Subclinical Hypothyroidism as a Risk for Coronary Artery Bypass Grafting
Background: The relationship between hypothyroidism and cardiovascular disease is well established. However, data on subclinical hypothyroidism (SH) and its impact on major adverse cardiovascular events (MACEs) and postoperative complica...
Bibliographical & Catalog Notes
Description based on first issue.
Print issues ceased with v. 31 (2013).
Numbering changes to year only with 2019.
Also issued online.